Evidence map›Paper›PMID 41559683›Full record

ArticleJournal of nanobiotechnology2026

Injectable multi-component hydrogels for the treatment of ascites caused by hepatocellular carcinoma via anti-tumor and reduction of ascites generation.

Yuqin Yang, Jinchai Qi, Yingqi Lang, Meiling Wu, Yixiao Gu, Xinyue Lu, Minshu Wang, Qibiao Wu, Fuhao Chu, Mengru Cai and 1 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuqin Yang *Institute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China.
Jinchai Qi *Beijing University of Chinese Medicine , Beijing, 102488, China.
Yingqi Lang *Beijing University of Chinese Medicine , Beijing, 102488, China.
Meiling WuInstitute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China.
Yixiao GuInstitute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China.
Xinyue LuInstitute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China.
Minshu WangInstitute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China.
Qibiao WuFaculty of Chinese Medicine, and State Key Laboratory of Mechanism and Quality of Chinese Medicine , Macau University of Science and Technology , Macau, 999078, China.
Fuhao ChuBeijing University of Chinese Medicine , Beijing, 102488, China. chufhao@163.com.
Mengru CaiInstitute of Basic Theory for Chinese Medicine Academy of Chinese Medical Sciences , Beijing, 100700, China. cmr199711@163.com.
Keyang XuFaculty of Chinese Medicine, and State Key Laboratory of Mechanism and Quality of Chinese Medicine , Macau University of Science and Technology , Macau, 999078, China. kyxu@must.edu.mo.

Funding

Chinese Medicine Guangdong Laboratory HQCML-C-2024006Faculty Research Grant of the Macau University of Science and Technology FRG-25-078-FCFundamental Research Funds for the Central Public Welfare Research Institutes YZX-202401National Natural Science Foundation of China 82204600National Natural Science Foundation of China 8250112390Science and Technology Development Fund, Macau SAR 0098/2021/A2The Science and Technology Development Fund, Macau SAR 0021/2022/A3
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide, and malignant ascites (MA) caused by HCC is almost incurable. However, the efficacy of chemotherapy is limited by poor tumor drug targeting and the presence of an immunosuppressive microenvironment. Therefore, it is urgent to find drugs for dual-therapy that have both anti-tumor effect and reduction of MA production. Inspired by self-assembly of two molecules, we enriched the effective parts of Genkwa Flos (GK), which was decocted with glycyrrhizic acid (GA) from licorice, one pot of green synthesis of an injectable multi-component hydrogel of TCM (GK-GA). The GK-GA hydrogel demonstrated excellent injectability and sustained retention properties in the peritoneal cavity following intraperitoneal administration. In vivo pharmacodynamic experiments demonstrated potent therapeutic efficacy, achieving a 47.62% reduction in ascites formation at 6.25 mg/kg. By integrating network pharmacology, transcriptomics, and metabolomics, mechanistic studies revealed its dual therapeutic pathways against MA: (1) as a pro-apoptotic agent that significantly induces tumor cell apoptosis by elevating intracellular reactive oxygen species (ROS) levels via mitochondrial membrane potential depolarization, and modulat related proteins in the PI3K-AKT signaling pathway, and (2) as a metabolic regulator that effectively suppresses ascites formation by normalizing the aldosterone metabolic pathway. The method of self-assembly of supramolecular hydrogel by enriching the effective parts is more in line with the characteristics of multi-component, multi-pathway and multi-target comprehensive prevention and treatment of diseases in TCM, and offers a promising approach for novel drug development.

Indexed as

Antineoplastic AgentsAscitesCarcinoma, HepatocellularHydrogelsLiver NeoplasmsAnimalsApoptosisCell Line, TumorGlycyrrhizic AcidHumansMaleMembrane Potential, MitochondrialMiceMice, Inbred BALB CReactive Oxygen SpeciesSignal TransductionAntineoplastic AgentsGlycyrrhizic AcidHydrogelsReactive Oxygen SpeciesAldosterone metabolic pathwayAn injectable multi-component hydrogelApoptotic agentGK-GAMalignant ascites

Identifiers

PMID41559683
PMCPMC12828936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.